“Our first quarter performance reflects the successful integration of our Reliant acquisition as demonstrated by a nearly 50/50 split in revenue derived from our Thermage and Fraxel product lines,” said Stephen J. Fanning, Chairman of the Board, president and chief executive officer of Solta Medical. “We generated strong international sales growth during the quarter, and in the U.S. market our dual sales force concept has been well received by customers.”

The company’s reported results for the first quarter of 2009 include non-cash acquisition-related charges of $3.3 million, non-cash stock based compensation charges of $0.8 million, and severance costs of $0.1 million. The GAAP net loss for the quarter including these charges was $4.8 million, or $0.10 per share as against net loss of $2.2 million, or $0.09 per share reported for the first quarter of 2008. The non-GAAP net loss for the quarter excluding these charges was $0.6 million, or $0.01 per share as compared to a non-GAAP net loss of $0.3 million, or $0.01 per share reported for the first quarter of 2008.

“On a pro forma combined basis as if the acquisition of Reliant was in effect from October 1, 2008, our first quarter revenue of $25.2 million grew sequentially by approximately $5.1 million, or 25%, from the fourth quarter of 2008,” added Fanning. “In addition, our team is managing expenses, delivering strong gross margins, and continuing to drive innovation that benefits both our physicians and their patients.”

“Also important to note, in March we secured a long-term bank credit facility for $9.0 million with Silicon Valley Bank. We believe that with our cost containment initiatives, as well as our bank credit facility, we have the financial resources needed to execute our operating plans and achieve our financial goals for 2009,” Fanning concluded.

Financial Goals for 2009

The company reiterated the following financial goals for 2009:

Realize approximately $19 million in cost synergies as a result of the acquisition of Reliant Technologies, Inc.

Generate positive cash flow from operations and positive non-GAAP EBITDA for the full year

Achieve a non-GAAP gross margin of 70% for the year excluding non-cash amortization charges and other non-cash purchase price related adjustments.